Videos
Monoclonal Antibodies for Alzheimer Disease and Lecanemab’s Potential: Richard Isaacson, MD
October 21st 2022The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience during the Medical Crossfire session on the Alheimer pipeline that he took part in at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 7 minutes]
Differences Between Fenebrutinib and Other BTK Inhibitors: Stuart Silverman, MD
October 21st 2022The neurologist at Allegheny Health Network’s Neuroscience Institute provided insight on the mechanism of action of fenebrutinib and how it differs from other BTK inhibitors currently in development. [WATCH TIME: 3 minutes]
Focusing on the Future of Neurology at IFN 2022: Richard Isaacson, MD
October 20th 2022The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine provides commentary about his time at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 4 minutes]
Exponential Growth of Research, Biomarkers in Alzheimer Disease: Thomas Wisniewski, MD
October 19th 2022The director of NYU Langone’s Alzheimer’s Disease Research Center discussed noticeable advancements within the field of Alzheimer disease in recent years and how they contribute to gaining a better understanding of the disease. [WATCH TIME: 5 minutes]
Amylyx’s New Treatment for the ALS Patient Community: Lawrence Steinman, MD
October 17th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses what Amylyx’s FDA approved therapy means for the patient community and future research that may be performed regarding the dosage of the treatment. [WATCH TIME: 5 minutes]
Newborn Screening for Earlier Diagnosis of Duchenne Muscular Dystrophy: Emma Ciafaloni, MD
October 16th 2022The professor of Neurology and Pediatrics at University of Rochester Medical Center speaks spoke on the evolving treatments for Duchenne muscular dystrophy and the possibility of earlier diagnosis through newborn screening. [WATCH TIME: 4 minutes]
Long-Term Goals of Guidelines for Painful Diabetic Neuropathy: Brian Callaghan, MD, MS
October 14th 2022The associate professor at the University of Michigan described the ways recently published guidelines on diabetic neuropathies will change how conditions like Guillain-Barré syndrome and CIDP are managed. [WATCH TIME: 3 minutes]
AMX0035’s Safety as a Treatment for Patients with ALS: Lawrence Steinman, MD
October 12th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses the biggest takeaway from the FDA approval of Amylyx’s therapy, marketed as Relyvrio, and the availability of the treatment for patients with ALS. [WATCH TIME: 5 minutes]
Approval of AMX0035 and the Future of Clinical Trials for ALS: Lawrence Steinman, MD
October 11th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discussed updates in ALS research along with the need in future studies following AMX005’s (Relyvrio; Amylyx Pharmaceuticals) recent FDA approval. [WATCH TIME: 4 minutes]
Understanding the Complexity and Heterogenicity of Alzheimer Disease: Thomas Wisniewski, MD
October 11th 2022The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology discussed current knowns and unknowns about the pathology of Alzheimer disease. [WATCH TIME: 4 minutes]
Approach to Poststroke Neuromuscular and Motor Symptoms: Wayne Feng, MD, FAHA
October 10th 2022The division chief of stroke and vascular neurology at Duke Health provided insight on the nuances of poststroke neuromuscular symptoms and how they differ from other typically managed impairments. [WATCH TIME: 5 minutes]
Breakthrough in ALS With FDA Approval of AMX0035: Lawrence Steinman, MD
October 10th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses Amylyx’s therapy that was recently approved by the FDA, and what it means for the ALS community and the global healthcare industry. [WATCH TIME: 5 minutes]
